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Oslo, Norway
Both impaired and improved cognitive function after electroconvulsive therapy (ECT) 
in major depressive disorder (MDD) patients may occur. We have previously found 
improved cognitive function 6 weeks after ECT in this group. The aim of this study was 
to report 6-month follow-up results from the same prospective project monitoring cog-
nitive effects of ECT. Thirty-one patients with MDD were assessed with the MATRICS 
Consensus Cognitive Battery (MCCB), the Everyday Memory Questionnaire (EMQ), and 
the Montgomery–Åsberg Depression Rating Scale prior to, 6 weeks, and 6 months after 
ECT. Compared to baseline, the speed of processing, attention/vigilance, and reasoning/
problem solving test results were significantly improved. The depression score was sig-
nificantly reduced. There were no changes in subjective memory complaint. There was 
no significant relationship between the EMQ and the MCCB subtests, but a significant 
correlation between current depression level and the EMQ. Six months after ECT the 
cognitive improvement reported at 6-week follow-up was maintained and extended. The 
corresponding decrease in depressive symptoms and stability in subjectively reported 
memory complaints suggest that the antidepressant effects of ECT do not occur at the 
expense of cognitive function.
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inTrODUcTiOn
Electroconvulsive therapy (ECT) is a potent method for inducing symptom relief in treatment-
resistant depression. However, fear of cognitive side effects, such as memory loss and confusion, is 
often cited as the main reason for not consenting to this type of treatment (1).
The literature on cognitive function after ECT for major depressive disorders (MDDs) is incon-
clusive, with reports of both impaired (2) and improved (3) cognitive capacity during the first 
weeks after treatment. Limitations of previous research are lack of longitudinal studies beyond 
the first few months after ECT and the assessment of few cognitive functions. The Sackeim et al. 
(2) study presents comprehensive cognitive function data from a relatively long time period after 
ECT (6 months) and reports deficiencies in speed of processing and autobiographic memory at 
this time point, whereas the other cognitive functions assessed were returned to normal. However, 
their participant group was heterogeneous in that some of the patients received square wave, brief 
TaBle 2 | Medication (cDD) before and 6 months after ecT.
Pre ecT (N = 29) Post ecT (N = 26)
Antidepressants 2.5 1.5
Antipsychotics 1.1 0.8
Lithium 0.8 0.8
Anticonvulsants 0.6 0.6
CDD, calculated dose of medication based on the prescribed dosage divided by the 
average recommended daily dosage.
TaBle 1 | Demographic characteristics of the participants (N = 31).
Age (years) 46.0 (SD 10.4)
Gender n = 11 (35.5%) men
n = 20 (64.5%) women
Education
Elementary school n = 8 (25.8%)
High school n = 13 (41.9%)
BA/BA+ n = 10 (32.3%)
Years since first onset of depression 20.8 (SD 10.5, range 5–40)
Age and years since onset in mean.
BA, Bachelor degree.
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pulse stimulation, while others were treated with sine wave ECT. 
Sine wave stimulation is no longer recommended, as it is related 
to stronger cognitive side effects than square pulse methods 
(4). Thus, there is a need for longitudinal studies of the effects 
of square wave stimulation. Currently, we follow depression 
patients for 2 years after square wave, brief pulse ECT, employing 
a comprehensive cognitive test battery, the MATRICS Consensus 
Cognitive Battery (MCCB) (5).
The MCCB was developed for neurocognitive assessment in 
schizophrenia spectrum disorders but may also be of utility in 
bipolar disorder (6–8) and MDD patients (9). The Norwegian 
version of the battery is currently used for monitoring cognitive 
effects of ECT in bipolar disorder (10) and MDD (11). A par-
ticular advantage of the MCCB is that it consists of tests assumed 
to withstand test–retest effects and thus permits repeated testing 
within relatively short time spans without biasing the results due 
to learning effects.
Previously, we have reported statistically significant improve-
ments in cognitive function, i.e., speed of processing, attention/
vigilance, and visual learning, 6 weeks after ECT as compared to 
baseline (11). Moreover, there was no significant change in subjec-
tive cognitive complaints from baseline, although the post ECT 
self-report of cognitive complaints was correlated with residual 
depression symptoms (11). This previous study gives cause for 
optimism regarding cognitive side effects of ECT. However, the 
first few weeks after treatment is usually an unstable period for 
many patients, with fluctuations in side effects, discharge from 
hospital, and social reorientation. The aim of the present paper 
is to assess cognitive function of the participants of the 6-week 
study at a time when the clinical picture is more stable, i.e., 
6 months after ECT.
MaTerials anD MeThODs
Participants
We assessed 31 Caucasian participants with an MDD episode 
recruited from the ECT clinical sections at Vestre Viken Hospital 
Trust and Vestfold Hospital Trust in South-Eastern Norway from 
March 2011 to November 2014.
At both of these time points, 31 patients participated. 
However, two of the patients from the 6-week follow-up test did 
not participate at 6 months due to relapse and excessive fatigue. 
Moreover, at the current time point, two of the patients who had 
been included at baseline but not participated at the previous 
assessment had recovered and were able to be tested. Therefore, 
the demographic data presented in Table 1 are slightly different 
from those described previously (11).
Inclusion criteria were age above 18 and below 70 years, capac-
ity for giving informed consent to both ECT and participation in 
this project, ability to understand spoken and written Norwegian, 
and a diagnosis of a treatment-resistant major depressive episode. 
The diagnosis of “treatment-resistant depression” was made by 
the clinicians based on previous lack of response to antidepres-
sant medication in combination with psychotherapy. Exclusion 
criteria were ongoing alcohol or drug abuse, ongoing neurologi-
cal illness, and ECT within the last 2 years.
clinical assessment
The diagnosis of a major depressive episode (F 32.1, F 32.2, F 32.3) 
was established by clinical interviews by hospital staff according 
to the ICD-10 criteria (12). Several different clinicians were 
involved in the diagnostic process. The patients were severely ill, 
and the decision to commence ECT was sometimes made so rap-
idly that the diagnostic process could not be undertaken by one 
and the same clinician. We did, however, rely on comprehensive 
information from the patients’ files to support the diagnosis made 
according to the ICD-10 system.
Twenty-four of the patients were diagnosed with recurrent 
unipolar depression (F 33) and seven with bipolar disorder type 
II (F 31) (12). Six had experienced psychotic symptoms during 
depressive episodes, 10 had moderate anxiety symptoms, and 4 
partially fulfilled the criteria for a personality disorder (emotion-
ally unstable personality disorder, F 60.3, and anxious personality 
disorder, F 60.6). Severity of depression was assessed with the 
Montgomery–Åsberg Depression Rating Scale (MADRS) (13), at 
the start of the neuropsychological assessment session.
Four of the patients had been treated with 1–2 series of ECT 
more than 2  years previously. All patients had discontinued 
their psychotropic medication 1–7 days before baseline testing. 
Medication for anxiety and/or insomnia had been permitted the 
evening before baseline testing. Two patients did not use any 
regular medication at baseline, and five were medicine-free at 
6 months after ECT. Calculated daily doses (CDD) of medication 
were based on the international daily doses of medication techni-
cal measurement system (14) (Table 2). A CDD is the outcome of 
the prescribed daily dose divided by the average recommended 
daily dose of medication.
electroconvulsive Therapy
No uniform ECT procedure was followed, and each treatment 
procedure was tailored to the individual patient. All patients 
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received square wave, brief pulse (0.5  ms) stimulation from a 
Thymatron system machine two (n = 3) or three (n = 28) times 
a week. The stimulation dose was age-based, i.e., the electrical 
current delivered was based on the patient’s age as percentage of 
504 mC. With unilateral electrode placement, the stimulation was 
4–6 times above seizure threshold and 2.25 times above seizure 
threshold with bilateral placement. Mean number of applications 
per ECT series was 11.9 (SD 4.1, range 6–23). Right unilateral 
electrode placement was used in 22 cases, bifrontal placement 
in 1 case, and mixed placement (switching from right unilateral 
to bifrontal in mid-series) in 8 cases. Anesthetic agents were 
alfentanil, propofol, or thiopental. Succinylcholine was used as 
a muscle relaxant. These pharmacological agents were adminis-
tered in dosages according to the physical characteristics of each 
participant.
After this first series and between the 6-week follow-up 
assessment, 6 patients received maintenance treatment with a 
mean 11.3 of applications (SD 6.0, range 5–18). Among these, 
four had right unilateral, one bifrontal, and one mixed electrode 
placement.
Between the 6-week and 6-month follow-up tests, 1 patient 
received a new series of ECT (9 applications) and maintenance 
treatment (13 applications) with right unilateral electrode 
placement.
The participants were cognitively assessed 1–3 days before the 
start of ECT, 6 weeks, and 6 months after completion of ECT. For 
the patients who received maintenance treatment, the follow-up 
cognitive assessments were performed 6 weeks or 6 months after 
the final application of ECT.
All participants signed an informed consent form before both 
testing sessions. These consents were given in addition to their 
consenting to ECT treatment, which was obtained by the clinical 
departments. The study was conducted according to the Helsinki 
Declaration and was approved by the Regional Committee for 
Research Ethics for Health Region South-East (REK Sør-Øst).
neuropsychological assessment
The cognitive assessment was carried out by a clinical psycholo-
gist with extensive neuropsychological training (CM). The par-
ticipants were tested at their respective clinical wards at baseline 
and at their respective outpatient clinic or at home at follow-up.
The MCCB covers 7 cognitive domains using 10 subtests 
(5, 15):
Speed of Processing, consisting of the subtests Trail Making 
Test A (TMT-A) (16), Symbol Coding [Brief Assessment of 
Cognition in Schizophrenia; (17)], and Fluency [Category 
Fluency; (18)],
Attention/Vigilance, assessed by The Continuous Performance 
Test-Identical Pairs (CPT-IP) (19),
Working Memory, consisting of the subtests Spatial Span [The 
Wechsler Memory Scale; (20)] and Letter Number Span [The 
University of Maryland Letter Number Span test; (21)],
Verbal Learning, assessed by the revised Hopkins Verbal Learning 
Test [immediate recall; (22)],
Visual Learning, measured by the revised Brief Visuospatial 
Memory Test (23),
Reasoning/Problem Solving, assessed by the Mazes test 
[Neuropsychological Assessment Battery; (24)], and
Social Cognition, measured by the Managing Emotions part 
of the Mayer–Salovey–Caruso Emotional Intelligence Test 
(MSCEIT) (25).
For a detailed description of the tests and the Norwegian 
standardization process, see Mohn et al. (26). Although originally 
developed for schizophrenia spectrum disorder patients, we have 
previously demonstrated that the MCCB is capable of generating 
a separate neurocognitive profile in MDD patients compared to 
healthy controls (27).
The average time of completion of the MCCB is approximately 
60 min. Due to excessive fatigue, 4 patients did not perform the 
MSCEIT and 10 did not perform the CPT-IP test.
Norwegian T scores have been published for the 20–59 years 
age group (26). As the current study includes participants above 
60 years, the MCCB results are presented in raw scores.
After the completion of the MCCB, the patients filled in the 
Everyday Memory Questionnaire (EMQ) (28), assessing practical 
attention and memory functions in 28 items.
statistics
All statistical analyses were performed using IBM SPSS Statistics 
version 22. As we had three time points (baseline, 6 weeks, and 
6 months) and random missing data (for MSCEIT and CPT-IP, 
see above), a linear mixed model approach was appropriate for 
analyzing differences across time. In all models, a score of the 
MADRS, EMQ, or a cognitive test was the dependent variable, 
and time the fixed factor.
The relationships between the EMQ and the MCCB scores 
were investigated with Pearson’s correlations.
resUlTs
There was a large, significant reduction in the MADRS score 
from baseline to 6 weeks and 6 months. The EMQ score did not 
significantly change across time. The scores of 5 of the 10 MCCB 
tests were significantly improved across time: TMT-A, Symbol 
Coding, Fluency, Mazes, and CPT-IP, assessing the domains 
speed of processing, reasoning/problem solving, and attention/
vigilance, respectively. The cognitive functions assessed by the 
other five subtests were unaltered across time. At no point was 
there any cognitive deterioration compared to baseline (Table 3).
There was no significant association between the EMQ score 
and the MCCB test results (P > 0.05). The correlation between 
the MADRS and the EMQ scores was statistically significant 
(r = 0.49, P < 0.01).
DiscUssiOn
general Discussion
We have demonstrated that our previous findings of significantly 
improved neurocognitive function 6  weeks after ECT (11) are 
maintained at the 6-month follow-up point. The improvement 
of the subtests of the speed of processing (TMT-A, Symbol 
TaBle 3 | Depression levels, subjective cognitive function, and MaTrics consensus cognitive Battery test scores (raw scores) of the participants 
(N = 31).
Baseline mean (sD) 6 weeks post ecT mean (sD) 6 months post ecT mean (sD) T (sign.)
Montgomery–Åsberg Depression rating scale 33.8 (8.1) 15.6 (9.2) 17.7 (8.3) −7.01***
everyday Memory Questionnaire 104.0 (37.9) 107.9 (43.6) 98.5 (42.6) −0.67
speed of processing
Trail Making Test A 48.7 (25.8) 39.8 (21.4) 37.0 (16.5) −3.00**
Symbol coding 40.5 (13.0) 44.6 (12.0) 46.4 (12.9) 3.57***
Fluency 21.3 (8.5) 22.2 (6.4) 24.5 (7.0) 2.98**
Working memory
Spatial Span (The Wechsler Memory Scale) 13.2 (3.0) 13.6 (3.2) 14.2 (3.3) 1.88
Letter Number Span Test 12.3 (3.9) 12.6 (3.8) 12.6 (3.4) 0.74
Verbal learning
Revised Hopkins Verbal Learning Test 22.6 (6.0) 23.2 (6.2) 23.1 (6.3) 0.48
Visual learning
Revised Brief Visuospatial Memory Test 21.4 (8.6) 23.5 (8.0) 23.7 (7.6) 1.74
reasoning/problem solving
Mazes 13.5 (8.1) 13.9 (7.9) 16.1 (7.7) 2.62*
social cognition (n = 27)
Mayer–Salovey–Caruso Emotional Intelligence Test 93.7 (8.0) 94.6 (9.5) 95.3 (8.4) 1.40
attention/vigilance (n = 21)
Continuous Performance Test-Identical Pairs 2.5 (0.5) 2.7 (0.5) 2.8 (0.5) 4.12***
Results of the linear mixed model analyses.
*P < 0.05, **P < 0.01, ***P < 0.001.
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Coding, and Fluency) and attention/vigilance (CPT-IP) domain 
we reported at 6 weeks was sustained at 6 months. The other test 
results were stable across time, with no deterioration at any point. 
Moreover, the improvement at 6  months was extended to the 
reasoning/problem solving (Mazes) domain. The tests assessing 
these cognitive domains all rely on time, as high scores partly 
depend on fast task performance. Processing speed is among 
the functions most strongly affected by depression (27, 29), 
and clinical remission is likely to be accompanied by increased 
performance speed.
Improved neurocognitive function after ECT has been dem-
onstrated by others 15 days (3), 1 month (30), and 3 months (31) 
after cessation of treatment. At 6 months after ECT, Sackeim et al. 
(2) reported cognitive improvement in most domains assessed, 
with the notable exception of processing speed, which was still 
compromised. However, the authors explain that finding as the 
likely result of the employment of sinus wave stimulation in a 
sizable minority of the participants.
It may be argued that our results are influenced by test–retest 
effects. However, one of the aims behind the MCCB test selection 
and standardization procedure was the development of a battery 
that allows repeated assessments at relatively short intervals, 
and alternate forms of the tests are used when appropriate (32). 
A recent study of schizophrenia patients demonstrated limited 
practice effects in MCCB test results during a 4-week follow-
up period (33). Thus, with repeated assessments over longer 
intervals than 4 weeks, we have little reason to expect this type 
of bias.
There are several ways in which these results may be interpreted. 
First, it is possible that ECT boosts cognitive performance directly 
by inducing transient neuroplastic changes in the hippocampus 
and other cerebral regions involved in learning and memory (34). 
Alternatively, ECT may have indirect effects and lead to increased 
cognitive function via antidepressant properties. Impaired cog-
nitive function is common in depressive disorders (27, 29, 35), 
and cognitive performance may naturally increase following 
symptom remission. A third possibility is the joint neuroplastic 
and antidepressant effect of ECT. To our knowledge, no study has 
elucidated this topic through a combination of brain imaging and 
behavioral measures, and we are unable to determine which of 
these hypotheses best explains our results.
Across time, there was no statistically significant change in 
subjective memory problems, as assessed by the EMQ. Of note, 
there was no significant correlation between the EMQ and objec-
tive neuropsychological performance at the current time point. 
Hence, the modest association between the EMQ and two MCCB 
tests we obtained at 6 weeks had disappeared (11), and the cogni-
tive problems our participants may experience on a daily basis 
were not reflected in the test scores. This discrepancy may be 
explained by the depressed participants’ low confidence in their 
own cognitive capacity. Alternatively, the EMQ and the MCCB 
tap different aspects of cognitive function, the former providing 
an estimate of naturalistic function, and the latter assessing a few 
functions during a highly structured test situation with thorough 
instructions of behavior.
Relatedly, in our previous study of the same participants 
6  weeks after ECT, we found a statistically significant positive 
association between the EMQ score and the MADRS score 
(11). We found the same relationship in the current study. 
This indicates that the depressive symptoms and the subjective 
5Mohn and Rund Cognition after ECT
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experience of cognitive dysfunction may be two sides of the 
same coin (11, 36). A limitation of our study is that we did not 
have sufficient statistical power to analyze subjective and objec-
tive cognitive function in subgroups divided according to their 
posttreatment symptoms of depression, so the above suggestion 
remains somewhat speculative. Nevertheless, when monitoring 
cognitive effects of ECT, we recommend that both objective and 
subjective function is recorded and seen in relation to residual 
depression symptoms.
strengths and limitations
Major strengths of this study are the employment of an inter-
nationally standardized, comprehensive cognitive test battery, 
a low drop-out-rate, a long follow-up period, and the cognitive 
assessment being performed at a stable clinical point.
The main limitation of our study is the relatively low N, 
rendering separate analyses based on gender, age, and diagnostic 
subgroups impossible. Women and elderly patients may display 
stronger cognitive side effects of ECT (2). Moreover, patients 
with symptoms of bipolar disorder or psychosis are generally 
more cognitively disadvantaged than MDD patients without such 
additional symptoms (37, 38), and it may be speculated that these 
patient groups exhibit different cognitive profiles after ECT. The 
fact that we were not able to control for these factors limits the 
generalizability of our results.
Relatedly, the low N may have generated type I errors. With 
more conservative statistics, some of our significant effects may 
not have occurred. Due to the exploratory nature of our study, 
however, we chose not to correct for multiple comparisons.
In addition, the ECT was not standardized, but tailored to each 
patient’s clinical characteristics. In our sample, both unilateral and 
bilateral electrode placement was used, and unilateral stimulation 
may generate less cognitive side effects than bilateral placement 
(2). A larger N would have enabled us to provide statistical con-
trol for the effects of electrode placement. Therefore, although 
ecologically valid, the present study may not satisfy the strictest 
methodological requirements.
A second limitation is our lack of control group comparisons. 
Analyses of cognitive function data from a group of MDD 
patients undergoing pharmacological and/or psychotherapeutic 
treatment would have enabled us to isolate the cognitive effects 
of ECT. However, a study comparing the MCCB test scores after 
ECT or pharmacological treatment of bipolar disorders (10) 
found no group differences in cognitive outcome. Still, a control 
group comparison would have put our findings on a more secure 
footing.
A third limitation is the fact that our participants were able to 
give their informed consent to ECT as well as to participation in 
this study. Our results may not generalize to those whose depres-
sion level is so high that they are unable to participate in research.
Finally, we did not assess autobiographical, episodic memory, 
a function that is often assumed to be negatively affected by ECT 
(1). The main reasons were the wish to spare a severely ill and 
fatigued group of participants another time consuming test and 
lack of psychometrically strong assessment tools of retrograde 
cognitive function in depressed individuals (39).
conclusion and clinical implications
This is the second report from our longitudinal study of the 
cognitive effects of ECT. Six months after treatment, cognitive 
improvement was maintained and expanded from the previous 
assessment at 6 weeks. There was no increase in subjective mem-
ory complaints after ECT. Despite methodological limitations, we 
are able to conclude that ECT does not seem to harm cognitive 
function as assessed by this test battery. On the contrary, we 
demonstrated cognitive improvement after ECT. The mechanism 
behind this effect is yet unknown, and future assessments in the 
current project will elucidate whether the cognitive improvement 
endures.
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